AllergoOncology: Biomarkers and Refined Classification for Research in the Allergy and Glioma Nexus - a Joint EAACI-EANO Position Paper

Aurelie Poli, Michelle Turner, Urszula Radzikowska, Denisa Ferastraoru, Mariona Pascal, Pieter Wesseling, Alex McCraw, Claudine Backes, Heather Bax, Christoph Bergmann, Rodolfo Bianchini, Luigi Cari, Leticia De las Vecillas, Elena Izquierdo, Frida Lind-Holm Mogensen, Alessandro Michelucci, Petr V. Nazarov, Simone P. Niclou, Giuseppe Nocentini, Markus Ollert, Matthias Preusser, Nataliya Rohr-Udilova, Andrea Scafidi, Reka Toth, Mieke Van Hemelrijk, Michael Weller, Uta Jappe, Maria Escribese, Erika Jensen-Jarolim, and Sophia Karagiannis

1Luxembourg Institute of Health
2Fundacion Privada Instituto de Salud Global Barcelona
3Universitat Zurich Schweizerisches Institut fur Allergie- und Asthmafororschung
4Montefiore Medical Center
5Hospital Clinic de Barcelona Centre de Diagnostic Biomedic
6Amsterdam UMC Locatie VUmc Afdeling Pathologie
7King’s College London School of Basic & Medical Biosciences
8RKM740 Interdisciplinary Clinics
9Medizinische Universitat Wien Zentrum fur Pathophysiologie Infektiologie und Immunologie
10Universita degli Studi di Perugia Dipartimento di Medicina e Chirurgia
11Instituto de Investigacion Hospital Universitario La Paz
12Universidad CEU San Pablo Facultad de Medicina
13Luxembourg Institute of Health Department of Infection and Immunity
14Medical University of Vienna
15King’s College London School of Cancer & Pharmaceutical Sciences
16UniversitatsSpital Zurich Neurologische Klinik
17Forschungszentrum Borstel Leibniz Lungenzentrum

November 9, 2023

Abstract

Epidemiological studies have explored the relationship between allergic diseases and cancer risk or prognosis in AllergoOncology. Some studies suggest an inverse association, but uncertainties remain, including in IgE-mediated diseases and glioma. Allergic disease stems from a Th2-biased immune response to allergens in predisposed atopic individuals. Allergic disorders vary in phenotype, genotype, and endotype, affecting their pathophysiology. Beyond clinical manifestation and commonly used clinical markers, there is ongoing research to identify novel biomarkers for allergy diagnosis, monitoring, severity assessment, and treatment. Gliomas, the most common and diverse brain tumours, have in parallel undergone changes in classification over...
time, with specific molecular biomarkers defining glioma subtypes. Gliomas exhibit a complex tumour-immune interphase and distinct immune microenvironment features. Immunotherapy and targeted therapy hold promise for primary brain tumour treatment, but require more specific and effective approaches. Animal studies indicate allergic airway inflammation may delay glioma progression. This collaborative European Academy of Allergy and Clinical Immunology (EAACI) and European Association of Neuro-Oncology (EANO) Position Paper summarizes recent advances and emerging biomarkers for refined allergy and adult-type diffuse glioma classification to inform future epidemiological and clinical studies. Future research is needed to enhance our understanding of immune-glioma interactions to ultimately improve patient prognosis and survival.

Hosted file
